慢性粒单核细胞白血病克隆性浆细胞样树突状细胞的生物学与预后影响
研究在159例慢性粒单核细胞白血病(CMML)患者骨髓中检测到32例(20%)存在CD123高表达、谱系阴性、BDCA-2/BDCA-4阳性的浆细胞样树突状细胞(pDC)增多,并证实其为克隆性、不依赖FLT3L积累,与调节性T细胞增多及急性白血病转化风险升高相关。
要点
- 159例CMML患者中32例(20%)骨髓存在谱系阴性CD123+BDCA-2+BDCA-4+的pDC增多。
- 分选单核细胞与pDC的全外显子测序显示两群细胞均携带RAS通路致癌基因体细胞突变。
- pDC增多与调节性T细胞积累及急性白血病转化风险升高相关。
核心结论
- CMML患者骨髓中可出现不依赖FLT3L的克隆性pDC积累,其与RAS通路突变相关,并与调节性T细胞积累及急性白血病转化风险升高相关。
研究设计与样本
- 采用多参数流式细胞术检测159例CMML患者骨髓,对分选单核细胞与pDC行全外显子测序,并结合常规与电镜、表面标志流式检测、基因表达分析及Toll样受体激动剂诱导干扰素α合成能力进行鉴定。
主要发现
- 159例患者中32例(20%)骨髓存在CD123+单核细胞增多,这些细胞谱系阴性、CD45+、CD11c-、CD33-、HLA-DR+、BDCA-2+、BDCA-4+。
- 分选单核细胞与pDC的全外显子测序在每例患者的两类细胞中均检出RAS通路致癌基因体细胞突变。
- CD34+细胞在缺乏FMS样酪氨酸激酶3配体(FLT3L)的条件下可生成大量pDC。
- pDC增多与调节性T细胞积累及急性白血病转化风险升高相关。
关键数值与推荐
- pDC增多的判定依据为骨髓中CD123+单核细胞增多且谱系阴性、CD45+、CD11c-、CD33-、HLA-DR+、BDCA-2+、BDCA-4+,在159例中检出32例(20%)。
- 克隆性证据为分选单核细胞与pDC中均检出RAS通路致癌基因体细胞突变。
- CD34+细胞在无FLT3L条件下可生成大量pDC。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Islands of CD123high cells have been commonly described in the bone marrow of patients with chronic myelomonocytic leukemia (CMML). Using a multiparameter flow cytometry assay, we detected an excess of CD123+ mononucleated cells that are lineage-negative, CD45+, CD11c-, CD33-, HLA-DR+, BDCA-2+, BDCA-4+ in the bone marrow of 32/159 (20%) patients. Conventional and electron microscopy, flow cytometry detection of cell surface markers, gene expression analyses, and the ability to synthesize interferon alpha in response to Toll-like receptor agonists identified these cells as bona fide plasmacytoid dendritic cells (pDCs). Whole-exome sequencing of sorted monocytes and pDCs identified somatic mutations in genes of the oncogenic RAS pathway in the two cell types of every patient. CD34+ cells could generate high amount of pDCs in the absence of FMS-like tyrosine kinase 3-ligand (FLT3L). Finally, an excess of pDCs correlates with regulatory T cell accumulation and an increased risk of acute leukemia transformation. These results demonstrate the FLT3L-independent accumulation of clonal pDCs in the bone marrow of CMML patients with mutations affecting the RAS pathway, which is associated with a higher risk of disease progression.
引用
- Lucas N, Duchmann M, Rameau P, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019. PMID: 30894665. doi:10.1038/s41375-019-0447-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。